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abortion at home and in a clinic: a systematic review
Thoai D Ngo,a Min Hae Park,b Haleema Shakura & Caroline Freea
Introduction
Medical abortion consists of using drugs to terminate a pregnan-
cy. It is an important alternative to surgical methods.1 Although 
many different drugs have been used, alone and in combination, 
to induce abortion, a regimen composed of mifepristone plus 
misoprostol has been the one most widely used since mifepris-
tone was first approved as an abortifacient in China and France 
in 1988.2 The World Health Organization (WHO) recommends 
this drug combination, with an initial dose of mifepristone 
followed by misoprostol 36 to 48 hours later, for early medical 
abortion.2 In 2005, an estimated 26 million women worldwide 
used this drug combination to terminate their pregnancies.3
In home-based medical abortion, a health-care provider 
administers mifepristone at the clinic and the pregnant woman 
later takes misoprostol at home. This protocol is intended to 
simplify the medical abortion regimen. Home-based medical 
abortion may improve the acceptability of medical abortion 
by allowing for greater privacy than in-clinic abortion, giving 
women greater control over the timing of abortion (anytime 
before the seventh week of pregnancy) and making it possible 
for family members or friends to be present to provide emotional 
support.4,5 Home-based medical abortion also reduces the num-
ber of clinic visits required, and hence the burden on women and 
services.5 In studies from France, Sweden, Tunisia and the United 
States of America, the majority of women opted for home-based 
medical abortion when offered the choice between home and 
clinic.3 Self-administration of misoprostol is already common 
in France and the United States.6
Medical abortion has been practiced to varying degrees 
across different settings. Despite this, whether home-based 
methods are as effective as clinic-based methods remains unclear. 
Studies evaluating regimens consisting of mifepristone and miso-
prostol in various combinations suggest that home-based medical 
abortion is effective and safe. Clinical trials from Canada,7 Tur-
key8,9 and the United States10,11 report rates of complete abortion 
ranging from 91% to 98% for pregnancies up to 9 weeks when 
misoprostol is administered at home (Appendix A, available 
at: http://www.mariestopes.org/documents/Home-based%20
Medical-Abortion-Systematic-Review-Appendix.pdf ). Obser-
vational studies12–20 have also shown that home-based medical 
abortion is well accepted and effective, with 86–98% of women 
reporting satisfaction with the method and complete abortion 
achieved in 87% to 98% of cases. However, none of these studies 
has compared home-based medical abortion with clinic-based 
protocols. To fill this research gap, in this paper we review the 
evidence on the comparative effectiveness, safety and acceptabil-
ity of medical abortion practised at home and in clinic.
Methods
Study selection
In this review we searched for published studies on home-
based medical abortion that tested different drugs, routes of 
administration and doses or regimens. Randomized controlled 
trials (RCTs) and prospective cohort studies were eligible for 
inclusion; service evaluations, case series and review articles 
were excluded. The inclusion criteria were: (i) a comparison 
between home-based and clinic-based medical abortion;(ii) a 
prospective assessment of outcomes; and (iii) reporting of the 
primary outcome of interest.
Abstracts in بيرع, 中文, Français, Pусский and Español at the end of each article.
Objective To compare medical abortion practised at home and in clinics in terms of effectiveness, safety and acceptability.
Methods A systematic search for randomized controlled trials and prospective cohort studies comparing home-based and clinic-based 
medical abortion was conducted. The Cochrane Central Register of Controlled Trials, EMBASE, MEDLINE and Popline were searched. 
Failure to abort completely, side-effects and acceptability were the main outcomes of interest. Odds ratios and their 95% confidence 
intervals (CIs) were calculated. Estimates were pooled using a random-effects model.
Findings Nine studies met the inclusion criteria (n = 4522 participants). All were prospective cohort studies that used mifepristone 
and misoprostol to induce abortion. Complete abortion was achieved by 86–97% of the women who underwent home-based abortion 
(n = 3478) and by 80–99% of those who underwent clinic-based abortion (n = 1044). Pooled analyses from all studies revealed no 
difference in complete abortion rates between groups (odds ratio = 0.8; 95% CI: 0.5–1.5). Serious complications from abortion were 
rare. Pain and vomiting lasted 0.3 days longer among women who took misoprostol at home rather than in clinic. Women who chose 
home-based medical abortion were more likely to be satisfied, to choose the method again and to recommend it to a friend than women 
who opted for medical abortion in a clinic.
Conclusion Home-based abortion is safe under the conditions in place in the included studies. Prospective cohort studies have shown 
no differences in effectiveness or acceptability between home-based and clinic-based medical abortion across countries.
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Participants
Participants of interest were women 
of reproductive age (15–49 years) in 
resource-rich or resource-limited settings 
who were seeking an abortion.
Outcomes
The primary outcome was the propor-
tion of successful abortions (i.e. com-
plete evacuation of the uterine contents 
without surgery). Other outcomes 
of interest were acceptability and the 
development of side-effects, which in-
cluded bleeding, vomiting, diarrhoea, 
fever, pain and infection. Mortality was 
expected to be low.2 There were three 
common measures of acceptability : 
satisfaction with the method, likelihood 
of choosing it again and likelihood of 
recommending it to a friend.21
Search strategy
We developed a search strategy based 
on search terms and filters used by the 
Cochrane Fertility Regulation Group22 
(Table 1). Ovid MEDLINE (1950–De-
cember 2009), EMBASE (1980–2010), 
Popline (2004–2010) and the Cochrane 
Central Register of Controlled Trials 
(1990–2010) were searched electroni-
cally. The following web sites were hand 
searched for relevant publications: Ma-
rie Stopes International, Ipas, Gynuity, 
Population Council, the International 
Consortium for Medical Abortion and 
Google Scholar. Searching was limited to 
publications from 1990 or later. No limits 
were placed on language.
Validity assessment
Open-label trials and prospective cohort 
studies were eligible for inclusion. Studies 
were excluded if outcome data were col-
lected retrospectively.
Study quality
Studies were assessed for quality based on 
a scale adapted from the Newcastle−Ot-
tawa Scale. They were awarded points 
based on:
i) Selection bias: “A” if same inclusion 
criteria for both study arms and “I” 
if different eligibility criteria for each 
study arm or if criteria unclear;
ii) Control for confounders: “A” if 
study controlled for gestational age 
in design/analysis (gestational age is 
an important confounder; previous 
reviews have indicated lower efficacy 
in more advanced pregnancies);23 “I” 
if no adjustment for confounders or 
this unclear.
iii) Assessment of gestational age: “A” 
if gestational age determined ac-
cording to standard protocol (i.e. 
interview, bimanual exam and/or 
ultrasound); “I” if not assessed or in-
adequately assessed; and
iv) Adequacy of follow-up: “A” if all 
study participants accounted for or 
if ≤ 10% lost to follow up; “I” if no 
description of those lost to follow-up 
and if drop-out rate > 10%.
To be categorized as high quality, stud-
ies had to score positively on selection 
bias, assessment of gestational age and 
adequacy of follow-up, as we felt that 
these three categories could have the 
most direct influence on the outcomes 
and study design.
Data abstraction
Two independent reviewers screened and 
extracted the data using a pre-designed 
form. A researcher who fluently spoke 
French and English translated the French-
language papers. We made three attempts 
within one month to contact the authors 
of studies whose eligibility for inclusion 
depended on unpublished information.
We recorded the number of women 
recruited to each intervention group and 
Table 1. List of databases and search termsa used in systematic review of studies comparing home-based and clinic-based medical 
abortion
Search Medline Embase Popline Cochrane central register of 
controlled trials
1 exp abortion, induced/ OR 
abortion.mp OR pregnancy 
termination.mp OR termination 
of pregnancy.mp
exp abortion/ OR exp medical 
abortion/ OR abortion.mp. 
OR exp induced abortion/ OR 
pregnancy termination.mp. OR 
exp pregnancy termination/ OR 
termination of pregnancy.mp
abortion/ medical abortion/ 
induced abortion/ pregnancy 
termination/ termination of 
pregnancy
abortion OR medical abortion OR 
induced abortion OR pregnancy 
termination OR termination of 
pregnancy
2 Mifepristone.mp. OR exp 
Mifepristone/ OR misoprostol.
mp. OR exp Misoprostol/ 
OR methotrexate.mp. OR 
exp Methotrexate/ OR exp 
Dinoprost/ OR dinoprost*.mp 
OR carboprost.mp. OR exp 
Carboprost/ OR sulprostone.
mp OR gemeprost.mp OR 
meteneprost.mp OR lilopristone.
mp OR onapristone.mp OR 
epostane.mp OR exp Oxytocin/ 
OR oxytocin.mp OR RU 486.mp 
OR mifegyne.mp
Mifepristone.mp. OR exp 
mifepristone/ OR misoprostol.
mp. OR exp Misoprostol/ 
OR methotrexate.mp. OR 
exp Methotrexate/ OR exp 
Dinoprost/ OR dinoprost*.mp 
OR carboprost.mp. OR exp 
Carboprost/ OR sulprostone.
mp OR gemeprost.mp OR 
meteneprost.mp OR lilopristone.
mp OR onapristone.mp OR 
epostane.mp OR exp Oxytocin/ 




Carboprost/ sulprostone / 
gemeprost / meteneprost / 
lilopristone / onapristone / 
epostane / Oxytocin/ RU 486 / 
mifegyne
Mifepristone OR Misoprostol OR 
Methotrexate OR Dinoprost* OR 
Carboprost OR sulprostone OR 
gemeprost OR meteneprost OR 
lilopristone OR onapristone OR 
epostane OR Oxytocin OR RU 
486 OR mifegyne
3 home.mp OR (home adj2 
use*).mp OR (home adj2 
administrat*).mp
exp home/ OR home.mp OR 
(home adj2 use*).mp OR (home 
adj2 administrat*).mp
home / home use* / home 
administrat*
home OR home use* OR home 
administrat*
1 AND 2 AND 3 1 AND 2 AND 3 1 AND 2 AND 3 1 AND 2 AND 3
Results 88 104 108 17
a Unless otherwise stated, search terms are free text terms; exp indicates exploded MeSH term; adj indicates adjacency; asterisk (*) indicates unlimited truncation.
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the number of complete abortions. The 
drugs used, dose and route of administra-
tion were noted, along with each study’s 
inclusion and exclusion criteria. We used 
study participant characteristics at base-
line and inclusion/exclusion criteria to 
qualitatively assess clinical heterogeneity.
Data synthesis
The principal measure of effect was the 
odds of having a successful medical abor-
tion at home relative to the odds of having 
a successful medical abortion in clinic 
and the 95% confidence interval (CI) of 
this odds ratio (OR). We calculated the 
odds of having a successful abortion us-
ing the number of women recruited for 
each study and an intention-to-treat ap-
proach. We synthesized effectiveness in a 
meta-analysis, specifying a random-effects 
model to produce a pooled OR and CI. 
This model was selected a priori to incor-
porate the effect of trial heterogeneity 
among prospective studies from different 
settings. Statistical heterogeneity was as-
sessed using χ2 tests and I2 statistics. The 
following sensitivity analyses were carried 
out: (i) separate analysis of high-quality 
studies to explore the effect of biases on 
study heterogeneity; (ii) analyses by maxi-
mum gestational age, and (iii) analyses 
by resource-rich versus resource-limited 
study setting.
We present a forest plot showing 
relative risks and 95% CIs for the primary 
outcome. Owing to the small number of 
studies included in the data synthesis, we 
did not assess publication bias. Analyses 
were carried out using Stata version 11 
(StataCorp. LP, College Station, USA).
Results
Description of included studies
Nine studies were included in this review 
(Fig. 1) (one study was conducted in both 
Tunisia and Viet Nam and we present the 
findings separately for each setting). All 
were prospective cohort studies and in-
cluded a total of 4522 participants (3478 
home users, 1044 clinic users) (Table 2). 
The studies were carried out in Albania 
(n = 409), France (n = 714 women), In-
dia (n = 599), Nepal (n = 400), Tunisia 
(n = 518), Turkey (n = 208) and Viet Nam 
(n = 1674), between 199724–2008.25,31
Study participants
The mean age of study participants ranged 
from 24.7 to 32.2 years. The maximum 
gestational age was 56 days in seven stud-
ies and 49 days in the two French stud-
ies. Gestational age was assessed by last 
menstrual period (LMP) and confirmed 
by clinical examination.
One Vietnamese study30 reported 
that home users were more educated and 
had a lower gestational age and higher gra-
vidity on average, and that fewer of them 
were primigravidas when compared with 
clinic users. An Indian study reported 
that home users were 1.6 years older on 
average than clinic users (P = 0.008).25 
The Tunisian study indicated that women 
using the home-based abortion method 
were more educated than those who 
opted for a clinic-based method.28 One 
study did not compare participant char-
acteristics at baseline.27
Interventions
In all studies, oral mifepristone and 
misoprostol were used in combination 
Fig. 1. Summary of study selection for systematic review of studies comparing home-
based and clinic-based medical abortion
Citations identified in search (n = 317)
Duplicates excluded (n = 239)
Potentially relevant studies
identified and screened for
retrieval evaluation (n = 178)
Studies excluded not revelant (n = 139)
Full-text articles retrieved for detailed evaluation (n = 39)
Studies excluded (n = 21)
13 no comparison group
3 no home-based medical abortion
2 studies of analgesic use
1 study of medical abortion for fetal death
1 retrospective study
1 subanalysis of included study
Potentially appropriate studies
to be included in review (n = 18)
+ 1 study identified through hand-searching
Studies withdrawn (n = 10)
5 Insufficient data on primary outcome of interesta
5 studies compare different regimens
of home-use medical abortion
(no comparison with clinic use)
Studies included in review and meta-analysis of efficacy data (n = 9)
a These studies involved medical abortion at home and in clinic but did not compare outcomes by home versus 
clinic status; data for this comparison were unavailable.
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to produce a medical abortion. In seven 
studies. 200 mg of mifepristone were used, 
while in the two French studies 600 mg 
were used.26,31 The time between mifepris-
tone and misoprostol administration was 
48 hours in seven studies, 36–48 hours 
in one French study31 and unspecified in 
another study.26 All studies used misopro-
stol 400 µg, given as two tablets of 200 
µg where specified.9,24,26,28,30 In all studies, 
women were given mifepristone at the 
clinic but could choose between taking 
misoprostol at home or returning to take 
it at the clinic. All protocols detailed the 
use of painkillers (paracetamol, codeine 
or ibuprofen), which women were advised 
to take as needed. In seven studies women 
were followed up 2 weeks after mifepris-
tone administration, while in one study 
they were followed up at 10–20 days.31
Six studies required that participants 
live or work within 1 hour of the study 
site.24,26,27,29–31 In the French studies, 
women who lived farther than 1 hour 
away from the referral hospital were in-
eligible for the home-based protocol but 
were included in the study.
Study quality
The quality assessment based on four 
criteria described previously resulted in 
seven studies being categorized as high 
quality and two as low quality. Two 
studies scored 4/4,24,30 five studies scored 
3/49,25,27–29 and the two French studies 





Among the 3478 women who took 
misoprostol at home, the proportion who 
succeeded in having a complete abortion 
ranged from 86% in India25 to 97% in 
Albania.24 The average success rate in this 
group was 89.7% (95% CI: 88.7–90.7%) 
(Table 2). Among the 1044 women who 
took misoprostol in clinic, the success rate 
ranged from 80% in Turkey9 to 99% in 
France.26 The average success rate in this 
group was 93.1% (95% CI: 91.4–94.5%). 
The ORs for complete abortion at home 
versus in a clinic showed no difference 
in effectiveness in five studies.9,24,25,28,29 
In three studies (two French,26,31 one 
Vietnamese)30 medical abortion in clinic 
settings was found to be more effective, 
while in the study conducted in both 
Tunisia and Viet Nam abortion at home 
proved more effective (OR: 2.9; 95% CI: 
1.1–8.1).27 Pooled data from all nine stud-
ies showed no evidence of a difference in 
complete abortion rates (OR: 0.8; 95% 
CI: 0.5–1.5). However, study heterogene-
ity was high (I2: = 69.4%).
Subgroup analyses by study quality, 
maximum gestational age and study set-
ting were equivalent, as the two studies 
from France also had low quality assess-
ment scores and a maximum gestational 
age of 49 days (versus 56 days in the other 
studies). Pooled analysis of the seven high-
quality studies showed no difference in 
complete abortion rates between women 
who took misoprostol at home (n = 3215) 
and those who took it in clinic (n = 593) 
(OR: 1.1; 95% CI: 0.7–1.9; I2: 62.0%) 
(Fig. 2). Pooled analysis of the findings of 
the two French studies indicated a higher 
rate of successful abortion among women 
who took misoprostol in clinic (n = 263 
and 451) (OR: 0.2; 95% CI: 0.1–0.6).
Side-effects and complications
Side-effects were inconsistently reported 
across studies (Table 3). Pain and cramp-
ing were experienced by > 90% of women 
and lasted from 0.5 to 3 days.24 Pooled 
analysis of the mean number of days of 
pain from three studies indicated that 
pain lasted 0.3 days longer in women who 
took misoprostol at home (n = 1761) than 
in those who took misoprostol in clinic 
(n = 297) (weighted mean difference, 
WMD: 0.3 days; 95% CI: 0.1–0.5).9,24,30 
Vomiting was reported by 12–34% of 
women24,29 and lasted 0.3 days longer in 
women who took misoprostol at home 
(n = 1761) than in women who took 
misoprostol in clinic (n = 297) (WMD: 
0.32; 95% CI: 0.1–0.5). Fever also lasted 
longer in the former (n = 2058) than in the 
latter (WMD: 0.3 days; 95% CI: 0–0.6). 
Pooled analysis (n = 2058) showed no dif-
ference between home-based and clinic-
based abortion in the reported duration 
of nausea (WMD: 0.3 days; 95% CI: −0.2 
to 0.9), or the duration of heavy bleeding 
(WMD: 0.1 day; 95% CI: −0.1 to 0.4). In 
one study,30 women who took misoprostol 
at home were more likely to contact health 
services by phone or make unscheduled 
clinic visits (Table 2). In three other stud-
ies, women who took misoprostol in clinic 
were more likely to call clinic hotlines and 
make unscheduled visits than women who 
took misoprostol at home.9,27,29
Serious complications were rare. Four 
women had severe bleeding that required 
transfusion. Two of these women had 
taken misoprostol at home;29 where the 
other two women took the misoprosotol 
was not reported.25 Suspected infection 
requiring hospitalization occurred in one 
case,25 but where the woman took the 
misoprostol was not reported.
Acceptability
In reporting acceptability, most studies 
used the following criteria: satisfaction 
with the method (8 studies); the likeli-
hood of choosing the method again (9 
studies); and the likelihood of recom-
mending medical abortion to a friend (4 
studies) (Table 4). Of the women who un-
derwent a home-based medical abortion 
(n = 3138), 84–99% were satisfied. Their 
average satisfaction rate was 88.4% (95% 
CI: 86.9–89.1). Among women who took 
misoprostol in clinic (n = 867), 72–97% 
were satisfied. Their average satisfaction 
rate was 85.6% (95% CI: 82.6–87.4). 
Pooled analysis showed no difference in 
satisfaction rates between women taking 
misoprostol at home or in clinic (OR: 
1.46; 95% CI: 0.59–3.60; I2: 82.2%).
About 78–97% of home users (mean 
94.4%; n = 3239) and 40–93% of clinic 
users (mean 61.6%; n = 963) stated that 
they would choose medical abortion 
again. Women who took misoprostol at 
home were seven times more likely to 
choose medical abortion again than wom-
en who took misoprostol in clinic (pooled 
OR: 7.1; 95% CI: 2.7–18.6), although 
heterogeneity was high (I2: 94%). Four 
studies reported the number of women 
who would recommend medical abortion 
to a friend (n = 1194).26,28,29,31 The pooled 
OR was 2.8 (95% CI: 0.5–17.3). Thus, 
no difference was found in this respect 
between women who took misoprostol 
at home and in clinic.
Discussion
Medical abortion is an important alterna-
tive to surgical methods for the termina-
tion of pregnancy. Our review is the first 
to systematically compare home-based 
to clinic-based medical abortion. Other 
reviews have compared medical abortion 
methods by regimen22,23 and gestational 
age.23 We have shown that the rate of 
complete abortion among women using 
home-based medical abortion across 
diverse study settings is high (~90%), 
and there is no evidence of a difference 
in effectiveness when compared to clinic-
based protocols. The rate of complete 
abortion reported in our review is similar 
to the rates reported in other reviews. For 
example, the Cochrane Review of medical 
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methods for first trimester abortion noted 
success rates of > 90% in all studies.22 Loss 
to follow-up was low in the included stud-
ies (4% in home-based groups, and 6% in 
clinic-based groups).
This review has limitations. Meta-
analysis of the findings of non-random-
ized studies increases the possibility of 
biases,32 particularly self-selection bias 
stemming from the fact that women 
could choose between home-based and 
clinic-based medical abortion. As an il-
lustration, women wanting to keep the 
procedure confidential and concealed 
from family members would be more 
likely than others to choose clinic-based 
abortion. Only one study reported the 
findings with adjustment for potential 
confounders.30 Our reported effect sizes 
are unadjusted and residual confounding 
and other biases are likely to have affected 
the estimates and study heterogeneity. 
Thus, the pooled estimates should be 
interpreted with caution.
Data from this review are limited 
to pregnancies no longer than 56 days. 
Eight of the nine included studies assessed 
gestational age from the date of the last 
menstrual period, which, according to 
a recent trial (n = 4484) that compared 
this method with pelvic bimanual and 
ultrasound, is effective in determining 
gestational age for early medical abor-
tion.33 In all studies, participants were 
required to live or work within 1 hour of 
the study site and to be in good health, 
Table 4. Acceptability of home-based and clinic-based medical abortion in studies included in systematic review comparing home-
based and clinic-based medical abortion
Study Satisfied or highly satisfied 
with method (%)
Would choose method 
again (%)
Would recommend method to 
a friend (%)
H C MD H C MD H C MD
Akin et al. 20049 NR NR NR 94.0 44.4 49.6 NR NR NR
Bracken et al. 200624 90.6 90.3 0.3 95.6 40.4 55.2 NR NR NR
Bracken et al. 201025 90.7 92.3 −1.6 95.3 67.1 28.2 NR NR NR
Dagousset et al. 200426 98.5 72.2 26.3 77.5 59.5 18.0 78.8 50.67 28.13
Elul et al. 2001,27 Viet Nam 91.0 87.0 4.0 93.0 33.0 60.0 NR NR NR
Elul et al. 2001,27 Tunisia 94.0 91.0 3.0 96.0 69.0 27.0 NR NR NR
Hajri et al. 200428 96.3 89.4 6.9 96.5     89.4* 7.1 97.2 92.5* 4.7
Karki et al. 200929 88.3 97.2 −8.9 90.7 93.2 −2.5 92.9 98.6 −5.7
Ngoc et al. 200430 83.6 91.4 −7.8 96.1 38.5 57.6 NR NR NR
Provansal et al. 200931 98.0 92.9 5.1 91.1 79.6* 11.5 89.1 85.0 4.1
C, clinic; H, home; MD, mean difference; NR, not reported; *P < 0.05.





Subtotal (I 2 = 0.0%; P = 0.645)
Note: Weights are from random effects analysis.







83/104 16.17Akin et al.
0.94 (0.21–4.21) 245/361 46/48 8.42Bracken et al. 2006
0.77 (0.36–1.68) 453/530 61/69 16.07Bracken et al. 2010
2.95 (1.08–8.08) 260/276 33/39 13.12
2.30 (0.77–6.84) 233/241 76/82 12.16
Elul et al.
Hajri et al.
0.63 (0.30–1.34) 267/323 68/77 16.39
0.50 (0.26–0.98) 1231/1380 164/174 17.68
Karki et al.
Ngoc et al.
Subtotal (I 2 = 62.0%; P = 0.015) 1.11 (0.65–1.91) 2881/3215 531/593 100.00
Low quality
0.29 (0.12–0.72) 124/143 155/162 70.92Provansal et al.
0.20 (0.05–0.81) 114/120 286/289 29.08Dagousset et al.
0.26 (0.12–0.56) 238/263 441/451 100.00
CI, confidence interval; OR, odds ratio.
a Pooled data from all nine studies showed no evidence of a difference in complete abortion (odds ratio: 0.8; 95% confidence interval: 0.5–1.5).
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and in several studies they were required 
to have access to a telephone. However, 
there was no stipulation regarding the 
means of transportation for getting to 
the study site or the presence of another 
person at home in case of emergency. 
Women participating in studies were also 
screened for allergies to mifepristone and 
misoprostol. The effectiveness of home-
based medical abortion in non-research 
settings without the precautionary mea-
sures and support systems that were most 
likely in place in these and other studies, 
essential for compliance with ethical 
norms, may be less satisfactory. From the 
data provided in this paper it is not pos-
sible to determine just how safe medical 
abortion practised at home would be if 
back up safety measures (e.g. easy access 
to a health facility, consultation by phone) 
were absent or more relaxed. Home-based 
medical abortion does not preclude prior 
screening for ectopic pregnancy, which is 
a standard of care even in resource-limited 
settings.34 Because of the inclusion of the 
two French studies, both categorized as 
low quality, this review was unable to 
provide robust estimates of the effective-
ness of home-based medical abortion in 
developed settings.
Safety data from the included studies 
showed that of 3478 women who under-
went abortion at home, two experienced 
heavy bleeding requiring transfusion. 
Thus, complications arising from use 
of misoprostol at home were rare. Two 
cases of heavy bleeding and one case of 
suspected infection were reported in the 
Indian study.25 However, the paper did 
not specify where the misoprostol was ad-
ministered. If we assume that it was always 
administered at home the proportions of 
women affected (0.03% with infection, 
0.1% with heavy bleeding) are compa-
rable to the proportions reported in other 
reviews.3,35 Most women experienced 
pain and cramping after misoprostol ad-
ministration. Women in the home-based 
groups reported experiencing pain and 
vomiting for slightly longer (0.3 days) 
than those in clinic-based groups, but they 
did not have more contact with health 
services. In the included studies, women 
who took misoprostol at home used 
self-report study cards to record any side-
effects, while those who aborted in clinic 
were observed in the facility. Therefore, 
the safety data may be subject to report-
ing bias. Data on side-effects were also 
inconsistently reported across studies and 
this limits their generalizability.
Women who practised home-based 
medical abortion appeared satisfied and 
likely to choose the method again. Ac-
ceptability is subject to the influence of 
costs and convenience, data that were 
unavailable for the included studies. Fur-
thermore, the included studies did not 
report on other factors, such as tolerance 
for bleeding and pain, that could have 
affected acceptability.
Our findings only apply to pregnan-
cies up to 56 days and to the oral use of 
mifepristone–misoprostol. Data from 
our review cannot be generalized to set-
tings where mifepristone is unavailable or 
where misoprostol is used in higher doses 
to induce abortion. It is also important 
to emphasize that the mifepristone-
misoprostol regimen is not an alternative 
contraceptive method.
Implications
There is no evidence that home-based 
medical abortion is less effective, safe 
or acceptable than clinic-based medical 
abortion. Simplified protocols could 
give greater access to medical abortion 
to women living in restrictive and/or 
resource-limited settings where mortality 
related to unsafe abortion remains high.36 
Adequate safety measures and support 
systems should be in place before home-
based medical abortion can be offered. To 
further clarify the comparative effective-
ness, safety and acceptability of home-
based medical abortion, further studies 
should be conducted to explore different 
regimens, routes of administration and its 
use for gestational ages, as well as on the 
use of misoprostol only for home-based 
medical abortion, given the high cost of 
mifepristone and the fact that its use is 
restricted in many settings. ■
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صخلم
ةيجهنم ةعجارم :ةدايعلاو لزنلما في يبطلا ضاهجلإا ةيلوبقمو ،ةملاسو ،ةّيلاعف ةنراقم
 ،ةّيلاعفلا  ثيح  نم  ةدايعلاو  لزنلما  في  ضاهجلإا  تاسرمام  ةنراقم  ضرغلا
.ةيلوبقلماو ،ةملاسلاو
 تاساردلاو دهاوشلا تاذ ةيئاوشعلا براجتلل يجهنم ثحب يرجأ ةقيرطلا
 لزنلما  في  سرايم  يذلا  يبطلا  ضاهجلإا  ينب  ةنراقملل  ةيقابتسلاا  ةيبارتلأا
 براجتلل  ةيزكرلما  Cochrane ناركوك تلاجس في ثحبلا  يرجأو .ةدايعلاو
 عاجترسا  طخو  ،EMBASE  ةيبطلا  تايطعلما  دعاوقو  ،دهاوشلا  تاذ
 ةيناكسلا  تامولعلما  تايطعم  دعاوقو  ،MEDLINE  ةيبطلا  تايشرنلا
 لشف  يه  هابتنلاا  طحم  ثحبلا  تاجرخم  تناكو  .Popline  تنترنلإا  لىع
 لصاوفو ةيحجرلأا بسن تَبِسُحو .ةيلوبقلماو ،ةيبناجلا راثلآاو ،ماتلا ضاهجلإا
.ةيئاوشعلا-تايرثأتلا جذونم مادختساب تاريدقتلا تَعِمُجو .95% ةقثلا
 ددع( ةساردلا في جاردلإا يرياعم عم قفاوتت تاسارد عست كانه ناك جئاتنلا
 ةيقابتسا  ةيبارتأ  تاساردلا  عيمج  تناك  .)ًاكراشم  4522  =اهيف  ينكراشلما
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Résumé
Efficacité, sécurité et acceptabilité comparatives de l’avortement médical à domicile et en clinique: une 
évaluation systématique
Objectif Comparer l’avortement médical pratiqué à domicile et en clinique 
en termes d’efficacité, de sécurité et d’acceptabilité.
Méthodes Une recherche systématique en essais contrôlés randomisés 
et en études prospectives de cohortes a été effectuée, comparant 
l’avortement médical à domicile et en clinique. Les recherches ont été 
réalisées dans le registre central Cochrane des essais contrôlés, dans 
EMBASE, MEDLINE et Popline. Les principaux résultats d’intérêt étaient 
l’échec d’un avortement complet, les effets indésirables et l’acceptabilité. 
Les rapports des cotes et leurs intervalles de confiance de 95% (IC) ont 
été calculés. Les estimations ont été regroupées à l’aide d’un modèle à 
effets aléatoires.
Résultats Neuf études ont répondu aux critères d’inclusion 
(n = 4 522 participants). Il s’agissait entièrement d’études prospectives 
de cohortes ayant utilisé la mifépristone et le misoprostol pour provoquer 
l’avortement. Un avortement complet a été obtenu par 86 à 97% des 
femmes qui ont subi l’interruption de grossesse à domicile (n = 3 478) 
et par 80 à 99% des femmes qui ont subi l’interruption de grossesse en 
clinique (n = 1 044). Les analyses regroupées de l’ensemble des études 
n’ont révélé aucune différence dans les taux d’avortement complet entre 
les groupes (rapport des cotes = 0,8; 95% IC: 0,5–1,5). Rares ont été 
les complications graves de l’avortement. Les douleurs et les nausées 
ont duré 0,3 jour de plus chez les femmes qui ont pris le misoprostol 
à domicile plutôt qu’en clinique. Celles qui ont choisi un avortement à 
domicile étaient plus enclines à être satisfaites, à choisir à nouveau cette 
méthode et à la recommander à une amie par rapport aux femmes qui 
ont opté pour l’avortement médical en clinique.
Conclusion L’avortement médical à domicile est sans danger s’il 
est effectué dans le respect des conditions établies dans les études 
examinées. Les études prospectives de cohortes n’ont montré aucune 
différence dans l’efficacité ou l’acceptabilité entre l’avortement médical 


























 ققحت  دقو  .ضاهجلإا  ثادحلإ  لوتسوربوزيمو  نوتسيبريفيم  تمدختساو
 لزنلما  في  ضاهجلإا  نيرجأ  تيلالا  ءاسنلا  نم  97% لىإ  86% في مات  ضاهجإ
 في ضاهجلإا نيرجأ تيلالا ءاسنلا في 99% لىإ 80% فيو ،)3478 =نهددع(
 مدع تاساردلل ةَع َّمَجُلما ليلاحتلا عيمج ترهظأو .)1044 =نهددع( تادايعلا
 =ةيحجرلأا ةبسن( ينتعومجلما ينب ماتلا ضاهجلإا تلادعم في فلاتخا دوجو
 ةيرطخ تافعاضم ثودح ردانلا نم ناكو .)1.5-0.5 :95% ةقثلا ةلصاف ؛0.8
 ءاسنلا ينب موي 0.3 رادقبم لوطأ ةدلم رمتساف ءيقلاو لملأا امأ .ضاهجلإا عم
 ناكو  .ةدايعلا  في هنذخأ  تيلالاب  ةنراقم  لزنلما  في لوتسوربوزيم  نذخأ  تيلالا
 ،ءاضر ثركأ حجرلأا لىع لزنلما في يبطلا ضاهجلإا نترخا تيلالا ءاسنلا روعش
 ةنراقم كلذو تاقيدصلل اهب ينصوأو ،ىرخأ ةرم ضاهجلإا ةقيرط نترخا ماك
.ةدايعلا في يبطلا ضاهجلإا نترخا نبم
 في ةََجردُلما  تاساردلا فورظ لظ في ًانومأم ليزنلما ضاهجلإا ناك جاتنتسلاا
 ينب تافلاتخا دوجو مدع ةيقابتسلاا ةيبارتلأا تاساردلا ترهظأ دقو .ثحبلا
.نادلبلا برع تادايعلا في وأ لزنلما في يبطلا ضاهجلإا ينب ةيلوبقلما وأ ةّيلاعفلا
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Resumen
Comparación de la efectividad, la seguridad y la aceptación de los abortos médicos practicados en el 
domicilio con aquellos realizados en la clínica: una revisión sistemática
Резюме
Сравнение эффективности, безопасности и приемлемости медикаментозных абортов, 
проведенных в домашних условиях и в гинекологической клинике: систематический обзор
Цель Сравнить медикаментозные аборты, проведенные в 
домашних условиях и в гинекологической клинике, с точки 
зрения эффективности, безопасности и приемлемости.
М е т о д ы  П р о в е д е н  с и с т е м а т и ч е с к и й  п о и с к 
рандомизированных контролируемых испытаний и 
проспективных когортных исследований, в которых 
сравнивались медикаментозные аборты, проводившиеся 
в домашних условиях и с гинекологической клинике. 
Поиск проводился по Центральному Кокрановскому 
регистру контролируемых испытаний и базам данных 
EMBASE, MEDLINE и Popline. Основными исходами, 
представляющими интерес, были: неудачный аборт, 
побочные эффекты и приемлемость. Производился расчет 
отношения шансов и их 95% доверительных интервалов 
(ДИ). Оценки объединялись с использованием модели со 
случайными эффектами.
Результаты Критериям включения соответствовали 
девять исследований (n = 4522 участников). Все они 
являлись проспективными когортными исследованиями, в 
которых, чтобы вызвать абортивный эффект, применялись 
мифепристон и мизопростол. Полный аборт был достигнут 
у 86–97% женщин, перенесших аборт в домашних условиях 
(n = 3478), и у 80–99% женщин, перенесших аборт в 
гинекологической клинике (n = 1044). Объединенный анализ 
данных всех исследований не выявил различий в показателях 
полного аборта между группами (отношение шансов = 0,8; 
95% ДИ: 0,5–1,5). Серьезные осложнения после аборта были 
редкими. У женщин, принимавших мизопростол дома, 
а не в гинекологической клинике, боли и рвота длились 
на 0,3 дня дольше. Вероятность того, что женщины будут 
удовлетворены, вновь выберут этот метод и рекомендуют 
его подруге, была выше для женщин, выбравших проведение 
медикаментозного аборта в домашних условиях, чем для 
женщин, выбравших проведения медикаментозного аборта 
в гинекологической клинике.
Вывод Проведение аборта в домашних условиях является 
безопасным, если местные условия соответствуют тем, что 
описаны в отобранных исследованиях. Проспективные 
когортные исследования не выявили различий 
между странами в эффективности или приемлемости 
медикаментозных абортов, проводившихся в домашних 
условиях и в гинекологической клинике.
Objetivo Comparar la efectividad, la seguridad y la aceptación de los 
abortos médicos practicados en el domicilio con aquellos realizados en 
la clínica.
Métodos Se realizó una búsqueda sistemática de ensayos clínicos 
controlados aleatorizados y de estudios de cohortes prospectivos, 
comparando los abortos médicos realizados en el domicilio y en la clínica. 
Se realizaron búsquedas en el Registro Central de Cochrane de Ensayos 
Controlados, EMBASE, MEDLINE y Popline. Los resultados de interés 
principales fueron el fracaso para abortar completamente, los efectos 
secundarios y la aceptabilidad. Se calcularon las tasas de probabilidad 
y sus intervalos de confianza (IC) del 95%. Se reunieron los cálculos 
aproximados utilizando un modelo de efectos aleatorios.
Resultados Nueve estudios cumplieron los criterios de inclusión 
(n = 4522 participantes). Todos fueron estudios de cohortes prospectivos 
que utilizaron mifepristona y misoprostol para inducir al aborto. El 
aborto completo se consiguió en el 86- 97% de las mujeres que se 
sometieron a un aborto en el domicilio (n = 3478) y entre el 80% y el 
99% de aquellas mujeres que se sometieron a un aborto en una clínica 
(n = 1044). Los análisis agrupados de todos los estudios no mostraron 
diferencias en las tasas de aborto completo entre los grupos (tasa de 
probabilidad = 0,8; IC del 95%: 0,5–1,5). Las complicaciones graves del 
aborto fueron poco frecuentes. El dolor y los vómitos duraron 0,3 días 
más en aquellas mujeres a las que se les administró misoprostol en el 
domicilio, en comparación con las que recibieron el tratamiento en la 
clínica. Las mujeres que optaron por un aborto médico en el domicilio 
mostraron un mayor grado de satisfacción, que las llevaría a elegir el 
método de nuevo y recomendárselo a una amiga, que aquellas mujeres 
que abortaron en la clínica.
Conclusión El aborto en el domicilio es seguro siempre que el lugar cuente 
con las condiciones incluidas en los estudios. Los estudios de cohortes 
prospectivos por país no han mostrado diferencias en cuanto a efectividad 
o aceptabilidad entre abortos médicos en el domicilio y en la clínica.
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